Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption (Q37624842)

21 August 2017

Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption (English)

1 reference

21 August 2017

0 references

1 reference

36

Anthony S Fauci

1 reference

21 August 2017

37

Pablo Tebas

1 reference

21 August 2017

Andrea R Shiakolas

24

0 references

John R. Mascola

34

object named as

John R Mascola

1 reference

21 August 2017

38

Tae-Wook Chun

1 reference

21 August 2017

32

Susan Moir

1 reference

21 August 2017

31

Barney S Graham

1 reference

21 August 2017

28

Julie E Ledgerwood

1 reference

21 August 2017

33

Richard A Koup

1 reference

21 August 2017

11

Gerald H Learn

1 reference

21 August 2017

6

Mary E Petrone

1 reference

21 August 2017

26

Nicole A Doria-Rose

1 reference

21 August 2017

30

Rebecca M Lynch

1 reference

21 August 2017

1

Katharine J Bar

1 reference

21 August 2017

13

Edward F Kreider

1 reference

21 August 2017

22

Sijy J O'Dell

1 reference

21 August 2017

35

James A Hoxie

1 reference

21 August 2017

4

J Shawn Justement

1 reference

21 August 2017

14

Jana Blazkova

1 reference

21 August 2017

16

Eric W Refsland

1 reference

21 August 2017

Katherine E Clarridge

18

object named as

Katherine E Clarridge

1 reference

21 August 2017

John Patrick Leo Madden

20

object named as

Patrick J Madden

1 reference

21 August 2017

25

Randall L Tressler

1 reference

21 August 2017

29

Edmund V Capparelli

1 reference

21 August 2017

2

Michael C Sneller

1 reference

21 August 2017

8

Catherine A Seamon

1 reference

21 August 2017

12

Michael A Proschan

1 reference

21 August 2017

10

Richard W Kwan

1 reference

21 August 2017

Linda J Harrison

3

1 reference

21 August 2017

Edgar T Overton

5

1 reference

21 August 2017

D Brenda Salantes

7

1 reference

21 August 2017

Benjamin Scheinfeld

9

1 reference

21 August 2017

Mark Bardsley

15

1 reference

21 August 2017

Michael Messer

17

1 reference

21 August 2017

Nancy B Tustin

19

1 reference

21 August 2017

KaSaundra Oden

21

1 reference

21 August 2017

Bernadette Jarocki

23

1 reference

21 August 2017

Robert T Bailer

27

1 reference

21 August 2017

language of work or name

English

0 references

publication date

9 November 2016

1 reference

The New England Journal of Medicine

21 August 2017

1 reference

21 August 2017

375

1 reference

21 August 2017

2037-2050

1 reference

21 August 2017

21

1 reference

HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1.

21 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Towards HIV-1 remission: potential roles for broadly neutralizing antibodies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

The size of the expressed HIV reservoir predicts timing of viral rebound after treatment interruption

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Antibody responses to envelope glycoproteins in HIV-1 infection

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Drift of the HIV-1 envelope glycoprotein gp120 toward increased neutralization resistance over the course of the epidemic: a comprehensive study using the most potent and broadly neutralizing monoclonal antibodies.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Broadly neutralizing antibodies suppress HIV in the persistent viral reservoir

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Phenotypic properties of transmitted founder HIV-1

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

The development of CD4 binding site antibodies during HIV-1 infection

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Antibody-based protection against HIV infection by vectored immunoprophylaxis

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

The development of combination therapies for HIV infection

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

The growth and potential of human antiviral monoclonal antibody therapeutics.

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

CD4+ count-guided interruption of antiretroviral treatment

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Therapeutic antibodies for human diseases at the dawn of the twenty-first century

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Recovery of replication-competent HIV despite prolonged suppression of plasma viremia

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation

23 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human monoclonal antibody VRC01 in healthy adults

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

HIV reservoirs as obstacles and opportunities for an HIV cure

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5292134

Re-emergence of HIV after stopping therapy

1 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27959728

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1608243

1 reference

21 August 2017

1 reference

21 August 2017

1 reference